Skip to main content
Toggle navigation
Search
Home
Browse by Speaker
Home
Browse by Speaker
Browse by Speaker
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
R
Raab, Marc
Dept. of Medicine V Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany
Clinical Research
Location: Hall FG
Marc Raab
(OA-13) Post-Induction Outcomes and Updated Minimal Residual Disease Analysis from GMMG-HD10/DSMM-XX (MajesTEC-5): A Study of Teclistamab-Based Induction Regimens in Newly Diagnosed Multiple Myeloma (NDMM)
Location: Room 701
Marc Raab
Raje, Noopur
Center for Multiple Myeloma, Massachusetts General Hospital, Harvard Medical School
Bispecifics
Location: Hall FG
Noopur Raje
IMS Educational Initiatives
Location: Hall FG
Noopur Raje
Managing myeloma with limited resources - challenges and opportunities
Location: Delta Hotel
Noopur Raje
Rajkumar, Vincent
Mayo Clinic
Core Session 1: Precursor Disease
Location: Hall FG
Vincent Rajkumar
IMWG-IMS consensus workshop summaries
Location: Hall FG
Vincent Rajkumar
Panel Discussion
Location: Hall FG
Vincent Rajkumar
Ramasamy, Karthik
University of Oxford and Oxford University Hospitals NHS FT
Can novel protein degraders mitigate T-cell exhaustion in MM? Learnings from preclinical studies
Location: Hall FG
Karthik Ramasamy
(PA-416) Optimizing Belantamab Mafodotin Doses for the Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma in the DREAMM-9 Study
Location: Room 714A
Karthik Ramasamy
Rashidian, Mohammad
Improving BCMA CAR T Cell Long-Term Efficacy for Reduced Relapse in Multiple Myeloma Patients
Location: Hall FG
Mohammad Rashidian
Reece, Donna
University Health Network, Princess Margaret Cancer Centre
Highlights of the 2025 Annual Meeting
Location: Hall FG
Donna Reece
Richardson, Paul
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
What more can we do: The first relapse treatment landscape
Location: Hall FG
Paul Richardson
Richter, Joshua
Icahn School of Medicine at Mount Sinai
Exploring clinical approaches
Location: Hall FG
Joshua Richter
Rivera, Joshua
Dana-Farber Cancer Institute
(OA-72) Deciphering Myeloid Cell Dynamics within the Osteolytic Lesion Tumor Microenvironment to Overcome Immunosuppression in Multiple Myeloma
Location: Room 718
Joshua Rivera
Rodriguez-Otero, Paula
Clinica Universidad de Navarra
Infection Risks with T-Cell Engaging Therapies
Location: Hall FG
Paula Rodriguez-Otero
(OA-68) Safety and Efficacy of Linvoseltamab (LINVO) in Patients (Pts) with High-risk Smoldering Multiple Myeloma (HR-SMM): First Results from the Phase 2 LINKER-SMM1 Trial
Location: Hall FG
Paula Rodriguez-Otero
Rosenberg, Aaron
UC Davis Comprehensive Cancer Center
(OA-18) The Value of Progression-Free Survival (PFS) from the Perspectives of Patients with Multiple Myeloma (MM) and Treating Physicians: Quantitative Research Findings from Eight Countries
Location: Room 701
Aaron Rosenberg
Rosinol, Laura
Hospital Clínic de Barcelona, IDIBAPS, Barcelona, Spain
Abstract Session 11
Location: Room 701
Laura Rosinol
Rosko, Ashley
The Ohio State University
Frailty adapted therapy in NDMM
Location: Hall FG
Ashley Rosko
Roulland, Sandrine
Inserm
Precursor States of Follicular Lymphoma
Location: Hall FG
Sandrine Roulland
Russell, Jennifer
University College London Hospital
(NSO-04) Patient Perspectives of Receiving Out-patient Step-up Dosing with Bispecific Antibodies (BsAb) for Relapsed Multiple Myeloma (MM)
Location: Room 501
Jennifer Russell
